ГОСТ Р ИСО 10993.16-99 Изделия медицинские. Оценка биологического действия медицинских изделий. Часть 16. Моделирование и исследование токсикокинетики продуктов деструкции и вымывания
ПРИЛОЖЕНИЕ Б
(справочное)
Библиография
[1] ISO 10993-2:1992, Biological evaluation of medical devices - Part 2: Animal welfare requirements
[2] ISO 10993-12:1996, Biological evaluation of medical devices - Part 12: Sample prepararation and reference materials
[3] Andersen M.E., Clewell H.J. Ill, Gargas M.L., Smith F.A. and Reitz R.H. Physiologically-based pharmacokinetics and the risk assessment process for methylene chloride. Toxicol. Appl. Pharmacol. 54: 100-116; 1987
[4] Bogen D.K. Simulation software for the Macintosh. Science 24: 138-142; 1989
[5] F.D.A. Guidelines for the format and content of the human pharmacokinetics and bioavailability section of an application. Department of Health and Human Services
[6] Hattis D., White P., Mamorstein L. and Koch P. Uncertainties in pharmacokinetic modelling for perchloroethylene. I. Comparison of model structure, parameters and predictions for low-dose metabolism rates derived by different authors. Risk analysis 10: 449-458, 1990
[7] Internatinal Programme on Chemical Safety (IPCS). Principles of toxicokinetic studies. Environmental Health Criteria 57, World Health Organization, Geneva, 1986
[8] ISO/TR 10993-9:1994 Biological evaluation of medical devices - Part 9: Degradation of materials related to biological testing
[9] Jollow D.J., Roberts S., Price V., Longacre S. and Smith C. Pharmacokinetic considerations in toxicity testing. Drug Metab. Rev. 13: 983-1007, 1982
[10] Katzper M. The uze of visual programming for pharmacokinetic and pharmacodynamic simulation. Centre for Drug Evaluation and Research, FDA, 5600 Fishers Lane, Rockville MD 20857
[11] Lin C.S., Shoaf S.E. and Griffiths J.C. Pharmacokinetic data in the evaluation of the safety of food and colour additives. Reg. Toxicol. Pharmacol. 15: 62-72, 1992
[12] Monro A.M. Interspecies comparisons in toxicology: The utilit and futility of plasma concentrations of the test substance. Reg. Toxicol. Pharmacol. 12: 137-160, 1990
[13] Organization for Economic Cooperation and Development (OECD). Guidelines for testing of chemicals - No 417 Toxicokinetics. OECD Publications
[14] Reitz R. Distribution, Persistence and elimination of toxic agents. In: Progress in Predictive Toxicology. Clayson D В et al. (eds.), Elsevier, New York, 1990
[15] Rowland M. and Tozer T.N. Clinical pharmacokinetiks: concepts and applications (2 edition). Lea and Febiger, Philadelphia, 1989
[16] Smith D.A., Humphrey M.J. and Charuel C. Design of toxicokinetic studies. Xenobiotica 20: 1187-1199, 1990
[17] Speid L.H., Lumley C.E. and Walker S.R. Harmonisation of guidelines for toxicity testing of pharmaceuticals by 1992. Reg. Toxicol. Pharmacol. 12: 179-211, 1990
[18] Travis C.B. Pharmacokinetics. In: Carcinogen Risk Analysis. Traves C.B. (ed) Contemporary issues. in risk analysis, vol. 3, Plenum Press, New York, 1988
[19] Wagner J.G. Pharmacokinetics for pharmaceutical scientists. Technomic publishing Co. Inc., Lancaster, 1994
[20] Wartak J. Clinical Pharmacokinetics, A modern approach to individualised drug therapy. Clinical Pharmacology and Therapeutics Series, Vol. 2. Praeger Publishers CBS Educational and Professional Publishing, 1983
[21] Weissinger J. Nonclinical pharmacologic and toxicologic considerations for evaluating biologic products. Reg. Toxicol. Pharmacol. 10: 255-263, 1989
[22] Welling P.G. Pharmacokinetic processes and mathematics. ACS Monograph 185. American Chemical Society, Washington DC, 1986
[23] Welling P.G., De La Iglesia F.A. Drug toxicokinetics. Marcel Dekker, Inc. New York, 1993
[24] Yacobi A., Skelly J.P. and Batra V.K. Toxicokinetics and new drug development, Pergamon Press, 1989
Электронный текст документа
подготовлен АО "Кодекс" и сверен по: